LONG-TERM SAFETY AND EFFICACY OF SB4 (ETANERCEPT BIOSIMILAR) IN PATIENTS WITH RHEUMATOID ARTHRITIS: COMPARISON BETWEEN CONTINUING SB4 AND SWITCHING FROM ETANERCEPT REFERENCE PRODUCT TO SB4

被引：13
|
作者：
Emery, P. [1 ]
Vencovsky, J. [2 ]
Sylwestrzak, A. [3 ]
Leszczynski, P. [4 ]
Porawska, W. [5 ]
Stasiuk, B. [6 ]
Hilt, J. [7 ]
Mosterova, Z. [8 ]
Cheong, S. Y. [9 ]
Ghil, J. [10 ]
机构：
[1] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[2] Inst Rheumatol, Prague, Czech Republic
[3] NZOZ Med Pro Familia Sp ZOO, Warsaw, Poland
[4] Poznan Univ Med Sci, Poznan, Poland
[5] Poznanski Osrodek Medyczny NOVAMED, Pultusk, Poland
[6] Medicome Sp ZOO, Oswiecim, Poland
[7] Ctr Terapii Wspolczesnej JM Jasnorzewska Sp Koman, Bialystok, Poland
[8] Revmactr MU Dr Mostera Sro, Brno, Czech Republic
[9] Samsung Bioepis Co Ltd, Suwon, South Korea
[10] Samsung Bioepis Co Ltd, Incheon, South Korea
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-eular.3137
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0150
引用
收藏
页码：236 / 236
页数：1
相关论文
共 50 条
  • [21] Etanercept (SB4): A Review in Autoimmune Inflammatory Diseases
    Celeste B. Burness
    Sean T. Duggan
    [J]. BioDrugs, 2016, 30 : 371 - 378
  • [22] ETANERCEPT ORIGINATOR VERSUS ITS BIOSIMILAR (SB4) FOR THE TREATMENT OF RHEUMATOID ARTHRITIS. ARE THEY TRULY SIMILAR?
    Rokad, Aasiyah
    Kearsley-Fleet, Lianne
    Watson, Kath
    Lunt, Mark
    Hyrich, Kimme L.
    [J]. RHEUMATOLOGY, 2022, 61 : I8 - I8
  • [23] EXPLORING EQUIVALENCE BETWEEN BIOSIMILAR SB4 AND REFERENCE ETANERCEPT BY ASSESSING EFFECTIVENESS IN RHEUMATOID ARTHRITIS PATIENTS TREATED IN ORDINARY CLINICAL PRACTICE
    Haugeberg, G.
    Bakland, G.
    Rodevand, E.
    Hansen, I. J. Widding
    Diamantopoulos, A.
    Pripp, A. H.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 543 - 543
  • [24] LONG TERM DRUG SURVIVAL FOR BIOSIMILAR SB4 ETANERCEPT IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS PATIENTS WITH A NON-MEDICAL SWITCH FROM ETANERCEPT REFERENCE DRUG
    Haugeberg, Glenn
    Fevang, Bjorg Tilde Svanes
    Bakland, Gunnstein
    Rodevand, Erik
    Diamantopoulos, Andreas
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 710 - 711
  • [25] MAINTENANCE AND IMPROVEMENT IN CLINICAL EFFICACY BETWEEN WEEK 12 AND 24 IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH SB4 OR REFERENCE ETANERCEPT
    Emery, P.
    Vencovsky, J.
    Keystone, E.
    Ghil, J.
    Cheong, S. Y.
    Hong, E. E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 834 - 834
  • [26] SWITCHING FROM REFERENCE PRODUCT ETANERCEPT TO THE BIOSIMILAR SB4 IN A REAL-LIFE SETTING: FOLLOW-UP OF 147 PATIENTS
    Sigurdardottir, V.
    Husmark, T.
    Svard, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 835 - 835
  • [27] SWITCHING FROM BIO-ORIGINAL ETANERCEPT TO BIOSIMILAR ETANERCEPT SB4: PATIENT ACCEPTABILITY AND OUTCOMES IN THE REAL WORLD
    Holroyd, C.
    Wallis, D.
    Bennett, S.
    Clayton, P.
    Edwards, C. J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1180 - 1180
  • [28] Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naive or Switching Patients: A Systematic Review
    Ebbers, Hans C.
    Pieper, Burkhard
    Issa, Amine
    Addison, Janet
    Freudensprung, Ulrich
    Rezk, Mourad F.
    [J]. RHEUMATOLOGY AND THERAPY, 2019, 6 (03) : 317 - 338
  • [29] A PHASE I PHARMACOKINETIC STUDY COMPARING SB4, AN ETANERCEPT BIOSIMILAR, AND ETANERCEPT REFERENCE PRODUCT (ENBREL®) IN HEALTHY MALE SUBJECTS
    Lee, Y. J.
    Shin, D.
    Kim, Y.
    Kang, J. W.
    Fuhr, R.
    Gauliard, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 718 - 718
  • [30] Erratum to: Etanercept (SB4): A Review in Autoimmune Inflammatory Diseases
    Celeste B. Burness
    Sean T. Duggan
    [J]. BioDrugs, 2016, 30 : 481 - 481
12345